Tegavivint
Advanced Hepatocellular Carcinoma (HCC) with Wnt/β-catenin mutations
Key Facts
About Iterion Therapeutics
Iterion Therapeutics is pioneering a novel approach to target the historically 'undruggable' Wnt/β-catenin signaling pathway in cancer. Its lead candidate, tegavivint, works by degrading the nuclear β-catenin co-activator TBL1, offering a potentially safer and more effective mechanism than upstream inhibitors. The company is advancing tegavivint in multiple clinical trials, with a primary focus on Wnt-mutated HCC, a population with no existing targeted therapies. Iterion's strategy includes expanding into other Wnt-driven solid tumors and hematologic malignancies, representing a significant multi-billion dollar market opportunity.
View full company profileAbout Iterion Therapeutics
Iterion Therapeutics is pioneering a novel approach to target the historically 'undruggable' Wnt/β-catenin signaling pathway in cancer. Its lead candidate, tegavivint, works by degrading the nuclear β-catenin co-activator TBL1, offering a potentially safer and more effective mechanism than upstream inhibitors. The company is advancing tegavivint in multiple clinical trials, with a primary focus on Wnt-mutated HCC, a population with no existing targeted therapies. Iterion's strategy includes expanding into other Wnt-driven solid tumors and hematologic malignancies, representing a significant multi-billion dollar market opportunity.
View full company profileAbout Iterion Therapeutics
Iterion Therapeutics is pioneering a novel approach to target the historically 'undruggable' Wnt/β-catenin signaling pathway in cancer. Its lead candidate, tegavivint, works by degrading the nuclear β-catenin co-activator TBL1, offering a potentially safer and more effective mechanism than upstream inhibitors. The company is advancing tegavivint in multiple clinical trials, with a primary focus on Wnt-mutated HCC, a population with no existing targeted therapies. Iterion's strategy includes expanding into other Wnt-driven solid tumors and hematologic malignancies, representing a significant multi-billion dollar market opportunity.
View full company profileAbout Iterion Therapeutics
Iterion Therapeutics is pioneering a novel approach to target the historically 'undruggable' Wnt/β-catenin signaling pathway in cancer. Its lead candidate, tegavivint, works by degrading the nuclear β-catenin co-activator TBL1, offering a potentially safer and more effective mechanism than upstream inhibitors. The company is advancing tegavivint in multiple clinical trials, with a primary focus on Wnt-mutated HCC, a population with no existing targeted therapies. Iterion's strategy includes expanding into other Wnt-driven solid tumors and hematologic malignancies, representing a significant multi-billion dollar market opportunity.
View full company profile